<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>EPHEDRINE SULFATE- ephedrine sulfate injection, solution </strong><br>Nexus Pharmaceuticals Inc<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>EPHEDRINE SULFATE INJECTION USP, 50 mg/mL
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">Forr IM, IV or SC Use
</p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Ephedrine Sulfate Injection, USP is a sterile solutionn of 50 mg ephedrine sulfate in Water for Injection.
</p>
<p>Ephedrine ooccurs as fine, white, oodorless crystals or powder and darkens on exposure to light. It is freely soluble in water and sparingly soluble in alcohol.
</p>
<p>The chemical name of ephedrine sulfate is (C<span class="Sub">10</span>H<span class="Sub">15</span>NO)<span class="Sub">2</span>•H<span class="Sub">2</span>SO<span class="Sub">4</span> benzenemethanol α-[l - (methylamino) ethyl] - sufate (2:1) (salt). Its molecular weight is 428 .54. The structural formula is:
</p>
<p><a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=16f212c3-d504-4d3c-813e-cc23a04aaa88&amp;name=eph03-0000-01.jpg"></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Ephedrine sulfate is a potent sympathomimetic that stimulates both α and β receptors and has clinical uses related to both actions. Its peripheral actions, which it owes in part to the release of norepinephrine, simulate responses that are obtained when adrenegenic nerves are stimulated. These include an increase in blood pressure, stimulation of heart muscle, constriction of arterioles, relaxation of the smooth muscle of the bronchi and gastrointestinal tract, and dilation of the pupils. In the bladder, relaxation of the detrusor muscle is not prominent, but the tone of the trigone and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> sphincter is increased.
</p>
<p>Ephedrine sulfate also has a potent effect on the CNS. It stimulates the cerebral cortex and sub-cortical centers, which accounts for its use in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span>.
</p>
<p>The cardiovascular responses reported in man include moderate <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, unchanged or augmened <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>, enhanced <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, variable alterations in peripheral resistance and usually a <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>. The action of ephedrine is more prominent on the heart than on the blood vessels. Ephedrine sulfate increases the flow of coronary, cerebral and muscle blood.
</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, administration of Ephedrine Sulfate Injection, USP produces a real but modest increase in motor power. The exact mechanism by which ephedrine sulfate affects skeletal muscle contractions is unknown.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Ephedrine Sulfate Injectionn, USP is indicated in the treatment of allergic disorders, such as bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> The drug has long been used as a pressor agent, particularly during spinal anesthesia when hypotensionn frequently ooccurs. In Stokes-Adams syndromeme with <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">complete heart block</span>, ephedrine has a value similar to that of epinephrine. It is indicated as a central nervous system stimulant in <span class="product-label-link" type="condition" conceptid="436100" conceptname="Narcolepsy">narcolepsy</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressive states</span>. It is also used in <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> to ephedrine sulfate are rare. The <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, if known, is a specific contraindication. Patients hypersensitive to other sympathomimetics may also be hypersensitive to ephedrine sulfate.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s7"></a><a name="section-6.1"></a><p></p>
<p class="First">GENERAL - Special care should be used when administering Ephedrine Sulfate Injection, USP to patients with heart disease, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and to patients receiving digitalis. Prolonged use may produce a syndrome resembling an <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety state</span>. Tolerance to ephedrine sulfate may develop, but temporary discontinuance to the drug restores its original effectiveness.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s8"></a><a name="section-6.2"></a><p></p>
<p class="First">DRUG INTERACTIONS - Concurrent use of ephedrine sulfate with general anesthetics, especially cyclopropane or halogenated hydrocarbons or digitalis glycosides may cause <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, since these medications may sensitize the myocardium to the effects of ephedrine sulfate.
</p>
<p>Therapeutic doses of ephedrine sulfate can inhibit the hypotensive effect of guanethidine, bethanidine, and debrisoquin by displacing the adrenergic blockers from their site of action in the sympathetic neurons. The effect in man is seen as a relative or a complete blockade of the antihypertensive drug by a sudden <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>. Concomitant use of Ephedrine Sulfate Injection, USP and oxytocics may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.
</p>
<p>Monoamine oxidase inhibitors may potentiate the pressor effect of ephedrine sulfate, possibly resulting in a <span class="product-label-link" type="condition" conceptid="312938" conceptname="Hypertensive encephalopathy">hypertensive crisis</span>. Ephedrine Sulfate Injection, USP should not be administered during or within 14 days following the administration of MAO inhibitors.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s9"></a><a name="section-6.3"></a><p></p>
<p class="First">PREGNANCY CATEGORY C - Animal reproduction studies have not been conducted with Ephedrine Sulfate Injection, USP.  Also, it is not known whether the drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Ephedrine Sulfate Injection, USP should be given to a pregnant woman only if clearly indicated.
</p>
<p>It is not known what effect Ephedrine Sulfate Injection, USP may have on the newborn or on the child's later growth and development when the drug is administered to the mother just before or during labor.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s10"></a><a name="section-6.4"></a><p></p>
<p class="First">NURSING MOTHERS - Ephedrine sulfate is excreted in breast milk. Use by nursing mothers is not recommended because of the higher than usual risks for infants.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s11"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">With large doses of ephedrine sulfate most patients will experience <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>. Some patients have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. Vesical sphincter spasm may occur and result in difficult and <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">painful urination</span>. <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> may develop in males with <span class="product-label-link" type="condition" conceptid="4016155" conceptname="Prostatism">prostatism</span>.
</p>
<p>Primordial <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> may occur following administration of Ephedrine Sulfate Injection, USP
</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s12"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span>
</h1>
<p class="First">Prolonged abuse of Ephedrine Sulfate Injection, USP can lead to symptoms of paranoid <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. When this occurs, patients exhibit such physical signs as <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, poor nutrition and hygiene, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">cold sweat</span> and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>.
</p>
<p>Some measure of tolerance may develop with prolonged or excessive use but addiction does not occur. Temporary cessation of medication and subsequent readministration restores its effectiveness.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s13"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">SYMPTOMS - The principal manifestation of ephedrine sulfate <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. In acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> the following signs and symptoms may occur: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respirations, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> and <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>. Initially, the patient may have <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, followed later by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> accompanied by <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>.
</p>
<p>TREATMENT - If respirations are shallow or <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> is present, artificial respiration should be administered. Vasopressors are contraindicated. In <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span> blood pressure should be maintained.
</p>
<p>ANTIDOTE - For <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, 5 mg phentolamine mesylate diluted in saline may be administered slowly intravenously, or 100 mg may be given orally. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may be controlled by diazepam or paraldehyde. Cool applications and dexamethasone 1 mg/kg, administered slowly intravenously, may control <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s14"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-10.1"></a><p></p>
<p class="First">ADULTS - T he usual parenteral dose is 25 to 50 mg given subcutaneously or intramuscularly. Intravenously, 5 to 25 mg may be administered slowly, repeated in 5 to 10 minutes, if necessary.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-10.2"></a><p></p>
<p class="First">CHILDREN - The usual subcutaneous or intramuscular dose is 0.5 mg/kg of body weight or 16 .7 mg/square meter of body surface every 4 to 6 hours.
</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s17"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Ephedrine Sulfate Injection USP, 50 mg/mL
</p>
<p>1 mL vial in packs of 10, NDC 14789-014-01
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s18"></a><a name="section-11.1"></a><p></p>
<p class="First"><span class="Bold">STORAGE:</span> Store at 20 ° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s19"></a><a name="section-12"></a><p></p>
<h1>Principal Display Panel - Carton Label
</h1>
<p class="First"><span class="Bold">NEXUS</span><br>PHARMACEUTICALS, INC.
</p>
<p>10 x 2 mL Vials  NDC 14789-014-01
</p>
<p><span class="Bold">Ephedrine Sulfate
</span><br>Injection, USP
</p>
<p><span class="Bold">50 mg/mL</span></p>
<p>1 mL fill in a 2 mL Vial
</p>
<p>Single Dose Vial
</p>
<p>Preservative Free
</p>
<p>For subcutaneous, <br>intramuscular or <br>intravenous use.
</p>
<p>Rx only
</p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel - Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=16f212c3-d504-4d3c-813e-cc23a04aaa88&amp;name=eph03-0001-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EPHEDRINE SULFATE 		
					</strong><br><span class="contentTableReg">ephedrine sulfate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:14789-014</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Ephedrine Sulfate</strong> (Ephedrine) </td>
<td class="formItem">Ephedrine Sulfate</td>
<td class="formItem">50 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:14789-014-01</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-DOSE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">06/08/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Nexus Pharmaceuticals Inc
							(620714787)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>d483665c-4eaf-495f-94ed-c155f5d45f1c</div>
<div>Set id: 16f212c3-d504-4d3c-813e-cc23a04aaa88</div>
<div>Version: 2</div>
<div>Effective Time: 20140601</div>
</div>
</div> <div class="DistributorName">Nexus Pharmaceuticals Inc</div></p>
</body></html>
